NR3C2 and type 2 diabetes mellitus: MR blockade has been shown to improve coronary flow reserve in individuals with type 2 diabetes, reducing their risk of cardiovascular disease (Garg et al., 2015), especially when added to an already optimized blockade of the RAAS (Barrera‐Chimal et al., 2022).